Abstract:The latest estimates from world health organization suggest that more than 450 million people are suffering from depression and other psychiatric conditions. Of these, 50-60% have been reported to have progression of gut diseases. In the last two decades, researchers introduced incipient physiological roles for serotonin (5-HT) receptors (5-HTRs), suggesting their importance as a potential pharmacological target in various psychiatric and gut diseases. A growing body of evidence suggests that 5-HT systems affect the brain-gut axis in depressive patients, which leads to gut comorbidity. Recently, preclinical trials of 5-HT4R agonists and antagonists were promising as antipsychotic and prokinetic agents. In the current review, we address the possible pharmacological role and contribution of 5-HT4R in the pathophysiology of chronic depression and associated gut abnormalities. Physiologically, during depression episodes, centers of the sympathetic and parasympathetic nervous system couple together with neuroendocrine systems to alter the function of hypothalamic-pituitary-adrenal (HPA) axis and enteric nervous system (ENS), which in turn leads to onset of gastrointestinal tract (GIT) disorders. Consecutively, the ENS governs a broad spectrum of physiological activities of gut, such as visceral pain and motility. During the stages of emotional stress, hyperactivity of the HPA axis alters the ENS response to physiological and noxious stimuli. Consecutively, stress-induced flare, swelling, hyperalgesia and altered reflexes in gut eventually lead to GIT disorders. In summary, the current review provides prospective information about the role and mechanism of 5-HT4R-based therapeutics for the treatment of depressive disorder and possible consequences for the gut via brain-gut axis interactions. This article is part of the special issue entitled 'Serotonin Research: Crossing Scales and Boundaries'.

New Role of the Serotonin as a Biomarker of Gut–Brain Interaction

Intestinal Crosstalk Between Microbiota and Serotonin and Its Impact on Gut Motility

Therapeutic potential of serotonin 4 receptor for chronic depression and its associated comorbidity in the gut

Serotonin, tryptophan metabolism and the brain-gut-microbiome axis

Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond

Gut-brain axis: A matter of health and disease in neuropsychiatric disorders…!

Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome

Gut Microbiota-Derived Short-Chain Fatty Acids: Novel Regulators of Intestinal Serotonin Transporter

Non-conventional features of peripheral serotonin signalling - the gut and beyond

Gut microbiota modulates neurotransmitter and gut-brain signaling

Serotonin Signaling to Regulate Energy Metabolism:A Gut Microbiota Perspective

Emerging Roles of Gut Serotonin in Regulation of Immune Response, Microbiota Composition and Intestinal Inflammation

Exploring the serotonin‐probiotics‐gut health axis: A review of current evidence and potential mechanisms

Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis

The Gut-Brain Axis and Its Role in Depression

Role of Gut Microbiota in the 5-Hydroxytryptamine Signal Transduction Mechanism

Effect of gut microbiome on serotonin metabolism: a personalized treatment approach

The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine

Advances in Studies on Serotonin Transporter in Intestinal Diseases

Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome.

Tryptophan Metabolites Along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease